<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305536</url>
  </required_header>
  <id_info>
    <org_study_id>NC27082017</org_study_id>
    <nct_id>NCT03305536</nct_id>
  </id_info>
  <brief_title>Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)</brief_title>
  <acronym>DECAV-K2</acronym>
  <official_title>Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital St. Georges, Ajaltoun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Omicron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nattopharma ASA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital St. Georges, Ajaltoun</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aortic Stenosis is a common but fatal disease when it becomes symptomatic, specially if not
      treated. Until now surgery remains the only reliable and effective treatment.

      In this study, the investigators will examine the effect of high dose of Menaquinone-7 (MK-7)
      supplementation (1000 mcg)/day on the progression of the aortic valve disease. The
      investigators hypothesize that MK-7 supplementation may slow or even reverse the progression
      of the disease process.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized clinical trial that will use Cardiac Echography and multi-detector
      computed tomography to compare the changes in the Aortic Valve Calcification Score (AVCS)
      over 3 years when using:

        1. 1000 mcg/d Vitamin K2 (menaquinone-7) + 5000 IU/d Vitamin D3

        2. 5000 IU/d Vitamin D3 as a control group
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the Aortic Valve Hemodynamic measured by echography: Change in Gradients in (mm Hg)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of the Aortic Valve Hemodynamic measured by echography: Change in Surface area in (cm2/m2)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of the Aortic Valve Hemodynamic measured by echography: Change in V max in (m/sec)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation of the MGP measured by the dp-uc MGP level which is a marker of vascular calcification.</measure>
    <time_frame>3 years</time_frame>
    <description>Lowering of dephosphorelated-undercarboxylated matrix Gla protein (dp-ucMGP picomol/l)
Reduction of the Aortic Valve Calcification Score(AVCS)
Improvement of dyspnea according to the New York Heart Association Classification(NYHA)
Improvement of the quality of life of the patients( physical activity, mobility)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of the Aortic Valve calcification measured by CT Scan</measure>
    <time_frame>3 years</time_frame>
    <description>Reduction of the Aortic Valve Calcification Score (AVCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of dyspnea (at rest and effort)</measure>
    <time_frame>3 years</time_frame>
    <description>Improvement of dyspnea according to the New York Heart Association Classification(NYHA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the quality of life of the patients</measure>
    <time_frame>3 years</time_frame>
    <description>ï»¿Every patient have to feel the WHOQOL-BREF, Questionnaire, June 1997, Updated 1/10/2014</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mcg/day of Vitamin K2 + 5000 IU/day Vitamin D3 as a treatment to decalcifiy the valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>interventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5000 IU/day of Vitamin D3 will be given to measure the progression of the disease along the time of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K2 (Menaquinone 7) + Vitamin D3</intervention_name>
    <description>Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease</description>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_label>interventional</arm_group_label>
    <other_name>K2/D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AVCS &gt; 300 without aortic valve stenosis requiring operation

          -  Focus on patients with:

               1. Bicuspid aortic valve

               2. Dialysis or CKD

               3. Statin treatment

        Exclusion Criteria:

          -  Use of Vitamin K antagonist

          -  Malabsorption Problem

          -  LVEF &lt; 40%

          -  A life expectancy &lt; 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rodoplh Frangi, MD</last_name>
    <phone>00961 9 234 202</phone>
    <phone_ext>1100</phone_ext>
    <email>drfrangi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Saint-George Ajaltoun</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolphe Frangi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital St. Georges, Ajaltoun</investigator_affiliation>
    <investigator_full_name>Rodolph Frangi</investigator_full_name>
    <investigator_title>Head of Department of Thoracic and Cardiovascular surgery</investigator_title>
  </responsible_party>
  <keyword>AVD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

